SUPERNUS PHARMACEUTICALS, INC. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 78/100
What the filing says
Supernus announced a definitive all-stock merger agreement with Indivior Pharmaceuticals, Inc. on August 3, 2026, creating a combined CNS-focused biopharmaceutical company. Q2 2026 total revenues reached $219.1M (+32% YoY), driven by growth products (Qelbree +15% to $89.2M, GOCOVRI +2% to $37.6M, ZURZUVAE collaboration revenue $35.4M, ONAPGO $13.5M). Company raised full-year 2026 guidance to $860–$890M total revenues and $150–$180M adjusted operating earnings (non-GAAP), up from prior $840–$870M and $140–$170M respectively.
Why this rating
Merger is transformational (significant M&A relative to $1.7B market cap), but contingent on regulatory/stockholder approval. Strong organic growth (+32% revenue, +52% growth products) is positive; Q2 net loss of $58.4M due to $54.9M APOKYN impairment is temporary non-cash charge. Merger creates uncertainty but no immediate cash drain.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.